Manuscripts and Publications

Filters: Author is Barr, R Graham  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
O
Paulin LM, Smith BM, Koch A, Han ML, Hoffman EA, Martinez C, Ejike C, Blanc PD, Rous J, R Barr G et al..  2018.  Occupational Exposures and Computed Tomographic Imaging Characteristics in the SPIROMICS Cohort.. Ann Am Thorac Soc. 15(12):1411-1419.
N
Labaki WW, Xia M, Murray S, Curtis JL, R Barr G, Bhatt SP, Bleecker ER, Hansel NN, Cooper CB, Dransfield MT et al..  2018.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.. Respir Med. 140:87-93.
Cooper CB, Paine R, Curtis JL, Kanner RE, Martinez CH, Meldrum CA, Bowler R, O'Neal W, Hoffman EA, Couper D et al..  2020.  Novel Respiratory Disability Score Predicts COPD Exacerbations and Mortality in the SPIROMICS Cohort.. Int J Chron Obstruct Pulmon Dis. 15:1887-1898.
M
Kesimer M, Smith BM, Ceppe A, Ford AA, Anderson WH, R Barr G, O'Neal WK, Boucher RC.  2018.  Mucin Concentrations and Peripheral Airway Obstruction in Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 198(11):1453-1456.
Zusman M, Gassett AJ, Kirwa K, R Barr G, Cooper CB, Han MK, Kanner RE, Koehler K, Ortega VE, Rd RPaine et al..  2021.  Modeling residential indoor concentrations of PM , NO , NO , and secondhand smoke in the Subpopulations and Intermediate Outcome Measures in COPD (SPIROMICS) Air study.. Indoor Air. 31(3):702-716.
Morris MA, Jacobson SR, Kinney GL, Tashkin DP, Woodruff PG, Hoffman EA, Kanner RE, Cooper CB, M Drummond B, R Barr G et al..  2018.  Marijuana Use Associations with Pulmonary Symptoms and Function in Tobacco Smokers Enrolled in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Chronic Obstr Pulm Dis. 5(1):46-56.
L
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.
Putcha N, Paul GG, Azar A, Wise RA, O'Neal WK, Dransfield MT, Woodruff PG, Curtis JL, Comellas AP, M Drummond B et al..  2018.  Lower serum IgA is associated with COPD exacerbation risk in SPIROMICS.. PLoS One. 13(4):e0194924.
Zou C, Li F, Choi J, Haghighi B, Choi S, Rajaraman PK, Comellas AP, Newell JD, Lee CHyun, R Barr G et al..  2021.  Longitudinal Imaging-Based Clusters in Former Smokers of the COPD Cohort Associate with Clinical Characteristics: The SubPopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS).. Int J Chron Obstruct Pulmon Dis. 16:1477-1496.
McKleroy W, Shing T, Anderson WH, Arjomandi M, Awan HAnees, Barjaktarevic I, R Barr G, Bleecker ER, Boscardin J, Bowler RP et al..  2023.  Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry.. JAMA. 330(5):442-453.
Li F, Choi J, Zou C, Newell JD, Comellas AP, Lee CHyun, Ko H, R Barr G, Bleecker ER, Cooper CB et al..  2021.  Latent traits of lung tissue patterns in former smokers derived by dual channel deep learning in computed tomography images.. Sci Rep. 11(1):4916.
I
Izquierdo M, Marion CR, Genese F, Newell JD, O'Neal WK, Li X, Hawkins GA, Barjaktarevic I, R Barr G, Christenson S et al..  2023.  Impact of Bronchiectasis on COPD Severity and Alpha-1 Antitrypsin Deficiency as a Risk Factor in Individuals with a Heavy Smoking History.. Chronic Obstr Pulm Dis. 10(3):199-210.
Haghighi B, Choi S, Choi J, Hoffman EA, Comellas AP, Newell JD, Lee CHyun, R Barr G, Bleecker E, Cooper CB et al..  2019.  Imaging-based clusters in former smokers of the COPD cohort associate with clinical characteristics: the SubPopulations and intermediate outcome measures in COPD study (SPIROMICS).. Respir Res. 20(1):153.
Esther CR, O'Neal WK, Anderson WH, Kesimer M, Ceppe A, Doerschuk CM, Alexis NE, Hastie AT, R Barr G, Bowler RP et al..  2022.  Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.. Chest. 161(5):1239-1249.
H
Smith BM, Traboulsi H, Austin JHM, Manichaikul A, Hoffman EA, Bleecker ER, Cardoso WV, Cooper C, Couper DJ, Dashnaw SM et al..  2018.  Human airway branch variation and chronic obstructive pulmonary disease.. Proc Natl Acad Sci U S A. 115(5):E974-E981.
G
Oelsner EC, Ortega VE, Smith BM, Nguyen JN, Manichaikul AW, Hoffman EA, Guo X, Taylor KD, Woodruff PG, Couper DJ et al..  2019.  A Genetic Risk Score Associated with Chronic Obstructive Pulmonary Disease Susceptibility and Lung Structure on Computed Tomography.. Am J Respir Crit Care Med. 200(6):721-731.
Hobbs BD, de Jong K, Lamontagne M, Bossé Y, Shrine N, Artigas MSoler, Wain LV, Hall IP, Jackson VE, Wyss AB et al..  2017.  Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.. Nat Genet. 49(3):426-432.
Sakornsakolpat P, Prokopenko D, Lamontagne M, Reeve NF, Guyatt AL, Jackson VE, Shrine N, Qiao D, Bartz TM, Kim DKyeom et al..  2019.  Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations.. Nat Genet. 51(3):494-505.
Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ et al..  2021.  Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.. Genome Med. 13(1):66.
F
Han MK, Quibrera PM, Carretta EE, R Barr G, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL et al..  2017.  Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort.. Lancet Respir Med. 5(8):619-626.
Ronish BE, Couper DJ, Barjaktarevic IZ, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG et al..  2022.  Forced Expiratory Flow at 25%-75% Links COPD Physiology to Emphysema and Disease Severity in the SPIROMICS Cohort.. Chronic Obstr Pulm Dis. 9(2):111-121.
E
J Wells M, Parker MM, Oster RA, Bowler RP, Dransfield MT, Bhatt SP, Cho MH, Kim V, Curtis JL, Martinez FJ et al..  2018.  Elevated circulating MMP-9 is linked to increased COPD exacerbation risk in SPIROMICS and COPDGene.. JCI Insight. 3(22)
Ortega VE, Li X, O'Neal WK, Lackey L, Ampleford E, Hawkins GA, Grayeski PJ, Laederach A, Barjaktarevic I, R Barr G et al..  2020.  The Effects of Rare Variants on Lung Function and Emphysema in SPIROMICS.. Am J Respir Crit Care Med. 201(5):540-554.
D
Couper D, LaVange LM, Han ML, R Barr G, Bleecker E, Hoffman EA, Kanner R, Kleerup E, Martinez FJ, Woodruff PG et al..  2014.  Design of the Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS).. Thorax. 69(5):491-4.
Oh AL, Mularski RA, Barjaktarevic I, R Barr G, Bowler RP, Comellas AP, Cooper CB, Criner GJ, Han MK, Hansel NN et al..  2021.  Defining Resilience to Smoking-related Lung Disease: A Modified Delphi Approach from SPIROMICS.. Ann Am Thorac Soc. 18(11):1822-1831.

Pages